

CODEN (USA): IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF

PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.398809

Available online at: http://www.iajps.com Research Article

DYSLIPIDEMIA IN PATIENTS WITH ESSENTIAL HYPERTENSION

Dr. Mashooq Ali Dasti*¹, Dr. Syed Fasih Ahmed Hashmi¹, Dr. Syed Zulfiquar Ali Shah², Dr. Hamid Nawaz Ali Memon³, Dr. Zulfiqar Ali Qutrio Baloch⁴ and Dr. Imran Karim²

Department of Cardiology, Liaquat University of Medical and Health Sciences (LUMHS)

Jamshoro.

²Department of Medicine, Liaquat University Hospital Hyderabad / Jamshoro.

³Zulekha Hospital, Dubai United Arab Emirates.

⁴Brandon Regional Hospital, Brandon, Florida.

Received: 27 February 2016 **Accepted:** 08March 2017 **Published:** 14 March 2017

Abstract:

OBJECTIVE: To determine the frequency of dyslipidemia in patients with essential hypertension.

PATIENTS AND METHODS: The descriptive case series study was conducted from July 2015 to December 2015 on the hypertensive individual. The inclusion criteria of the study were the patients of ≥ 30 years of age; either gender had history of essential hypertension (known cases) for more than 3 years duration. All the individuals were assessed for dyslipidemia after at least 14 hours fasting. The frequency / percentages (%) and means $\pm SD$ computed for study variables.

RESULTS: Total one hundred hypertensive individuals were recruited and study for dyslipidemia. The mean $\pm SD$ for age, systolic and diastolic blood pressure was 53.98 ± 5.87 , 150.87 ± 7.65 and 100.72 ± 5.85 . The frequency of dyslipidemia was 48 (68.5%) with male gender predominant (75%) along with urban population (65%). The mean $\pm SD$ for Triglycerides (mg/dl), Total cholesterol (mg/dl), High density lipoprotein (mg/dl), Low density lipoprotein (mg/dl) and Very low density lipoprotein (mg/dl) was 230 ± 10.76 , 265 ± 12.87 , 27.76 ± 2.98 , 160.72 ± 13.85 and 40.98 ± 9.53 while the serum triglyceride and cholesterol was observed to be raised in 12.5% and 12.5% and LDL 14.5% wheres the mix dyslipidemia was observed in 41.6%.

CONCLUSION: The correlation of dyslipidaemia and essential hypertension should be properly evaluated and treated to save the patients from long term chronic complications associated with hypertension and hyperlipidemia. **Keywords:** Hypertension, Lipid profile and Dyslipidemia.

Corresponding Author:

Dr. Mashoog Ali Dasti,

Department of Cardiology,

Liaquat University of Medical and Health Sciences (LUMHS),

Jamshoro.

Email: zulfikar229@hotmail.com,



Please cite this article in press as Mashooq Ali Dasti et al, **Dyslipidemia in Patients with Essential Hypertension**, Indo Am. J. P. Sci, 2017; 4(03).

INTRODUCTION:

Hypertension is a major health trouble and the cause of mortality worldwide and the lower socio economic community faces peak incidence for hypertension due to improper treatment[1,2]. In Pakistan, awareness of hypertension and related complication is very poor, although the educational strategies in other countries have effective role to reduce the burden of the disease[3]. In our daily practice we observed many individuals of different age group to diagnose as hypertension for the first time and sometimes presents with complications related to hypertension[4]. Thus, evaluating hypertension at initial age and sorting associated complications with appropriate treatment will not only increase life expectancy but also prevent to acquire the complications[5]. Hypertension is also associated with coronary heart disease and former literature had identified risk factors related to coronary heart diseases includes diabetes mellitus, dyslipidemia, weight gain (obesity), diet and sedentary life style[6,7]. Among all the kidney impairment is the major complication in subjects with chronic severe hypertension[8-10]. Lipid disorders hypertriglyceridemia, hypercholestrolemia, and low density lipoprotein have impact in the etiopathogenesis of hypertension associated with coronary arterial diseases and along with metabolic syndrome is a cluster of health trouble that needs immediate effective measure[11-13]. Therefore this study was conducted on hypertensive individuals to evaluate their lipid profile to detect the frequency and pattern of dyslipidemia as early treatment can save the patient to acquire the life threatening complications associated with hypertension and hyperlipidemia.

PATIENTS AND METHODS:

The descriptive case series study was conducted from July 2015 to December 2015 on the hypertensive individual. The inclusion criteria of the study were the patients of ≥ 30 years of age; either gender had history of essential hypertension (known cases) for more than 3 years duration while the exclusion criteria of the study were the patients with secondary hypertension, malignancy, pregnant ladies, tissue disorders, connective already corticosteroids or anti-hypertensive regimen and non cooperative individuals. After taking informed consent, the detail history was taken and relevant clinical examination was performed. The routine and specific investigations (if necessary) were advised while to evaluate the dyslipidemia the patients were advised for at least 14 hours fasting and then blood sample was drawn and sent to laboratory for biochemical analysis. The data was recorded on predesigned proforma while analyzed in SPSS 16. The frequency and percentages of categorical variables was calculated while for numerical variables the mean ±SD was used.

RESULTS:

Total one hundred hypertensive individuals were recruited and study for dyslipidemia. The mean ±SD for age, systolic and diastolic blood pressure was 53.98±5.87, 150.87±7.65 and 100.72±5.85. The frequency of dyslipidemia was 48 (68.5%) with male gender predominant (75%) along with urban population (65%). The results are given in Table 1-2.

Table 1: The Demographical, Clinical and Biochemical Profile of the Population

AGE (yrs)	Frequency (N=70)		Percentages (%)
30-39	08		11.4
40-49	20		28.5
50-59	30		42.8
60+	12		17.1
GENDER			
Male	50		71.4
Female	20		28.5
DYSLIPIDEMIA			
Yes		48	68.5
	Male	Female	
	36 (75%)	12 (25%)	
No	22		31.4
BLOOD PRESSURE			
Systolic	150.87±7.65		
Diastolic	100.72±5.85		
MEAN ±SD OF LIPID PROFILE			
Triglycerides (mg/dl)	230±10.76		
Total cholesterol (mg/dl)	265±12.87		
High density lipoprotein (mg/dl)	27.76±2.98		
Low density lipoprotein (mg/dl)	160.72±13.85		
Very low density lipoprotein (mg/dl)	40.98±9.53		

Table 2: The Frequency and Pattern of Dyslipidemia

PARAMETER	FREQUENCY (N=48)	PERCENTAGES (%)
↑TG	06	12.5
↑Cholesterol	06	12.5
↑LDL	07	14.5
↑VLDL	04	8.3
↓HDL	05	10.4
Mix dyslipidemia	20	41.6

DISCUSSION:

Dyslipidaemia in hypertension is due to lipid accumulation within the lumen of vessels leads to atherosclerosis and increases the resistance for blood flow in vascular system causing hypertension[14,15]. In present study the dyslipidemia was observed in 48(68.5%) individuals with male gender 36(75%). Majority of the population had mix dyslipidemia 20(28.5%), followed by ↑TG (12.5%) and ↑cholesterol (12.5%) and ↓HDL 5 (10.4%) respectively. The observations were also reported previously by several studies [16-18]. The HDL-cholesterol impairs endothelium dependent dilation

and is a protective protein which shown to be decrease in dyslipidemic hypertensive population suggesting more risk to acquire complications of hyperlipidemia. With chronic persistent hyperlipidemia the target organ damage is also ensues. In present study the HDL was found to be reduce in 10.4% population, the findings are consistent with former literature [19,20]. The low density lipoprotein is a vasoconstrictor proinflammatory, mitogenic, and thrombogenic protein, usually called as bad protein / culprit. Thus it's raise in hypertensive individuals increase the risk

to acquire complications of hypertension and hyperlipidemia [21,22].

In present study the LDL was raise in 7(14.5%) patients and it is consistent with the former study. In present series, the \(\frac{1}{4}TG\) and \(\frac{1}{4}cholesterol\) was observed in 12.5% and 12.5% hypertensive subjects. The finding was also reported previous by Onat A, et al and Eaton CB, et al. [23, 24] Hypertension is a degenerative disorder that not only increases purine metabolism and uric acid level but also affecting the blood vessels supplying various organs of the body and damage to these main organs is known as target organ damage [25] .The complication of hypertension as Heart failure has more endothelial dysfunction due to dyslipidaemia so in every hypertensive individual dyslipidaemia should be evaluated and corrected because early detection will prevent complications of hypertension and hyperlipidemia.

CONCLUSION:

Hypercholesterolmia, hypertriglyceridemia, low HDL and raised LDL and VLDL are seen in patients with essential hypertension. Thus correlation of dyslipidaemia and essential hypertension should be properly evaluated and treated to save the patients from long term chronic complications associated with hypertension and hyperlipidemia.

REFERENCES:

- 1.Kjeldsen SE, Aksnes TA, Ruilope LM. Clinical Implications of the 2013 ESH/ESC Hypertension Guidelines: Targets, Choice of Therapy, and Blood Pressure Monitoring. Drugs R D. 2014 Jun; 14(2): 31–43.
- 2.Gudina EK, Michael Y, Assegid S. Prevalence of hypertension and its risk factors in southwest Ethiopia: a hospital-based cross-sectional survey. Integr Blood Press Control. 2013; 6: 111–117.
- 3.Aziz KU. Evolution of systemic hypertension in Pakistani population. J Coll Physicians Surg Pak. 2015 Apr;25(4):286-91.
- 4. Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014 Jun; 32(6): 1170–1177.
- 5.Bhadoria AS, Kasar PK, Toppo NA, Bhadoria P, Pradhan S, Kabirpanthi V. Prevalence of hypertension and associated cardiovascular risk factors in Central India. J Family Community Med. 2014 Jan-Apr; 21(1): 29–38.
- 6.Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013 Sep 4;310(9):959-68

- 7.Bonsa F, Gudina EK, Hajito KW. Prevalence of Hypertension and Associated Factors in Bedele Town, Southwest Ethiopia. Ethiop J Health Sci. 2014 Jan; 24(1): 21–26
- 8.Bromfield S, Muntner P. High Blood Pressure: The Leading Global Burden of Disease Risk Factor and the Need for Worldwide Prevention Programs. Curr Hypertens Rep. 2013 Jun; 15(3): 134–13.
- 9. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. J Hum Hypertens. 2015 Apr;29(4):247-53.
- 10.Ogah SO, Okpechi I, Chukwuonye II, Akinyemi JO. Blood pressure, prevalence of hypertension and hypertension related complications in Nigerian Africans: A review. World J Cardiol. 2012 Dec 26; 4(12): 327–340.
- 11. Choudhury KN, Mainuddin AKM, Wahiduzzaman M, Islam SMS. Serum lipid profile and its association with hypertension in Bangladesh. Vasc Health Risk Manag. 2014; 10: 327–332.
- 12. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens. 1999 Jul;12(7):673-81.
- 13.Arshad AR, Tipu HN, Paracha AI. The impact of hypertension on lipid parameters in type 2 diabetes. J Pak Med Assoc. 2016 Oct;66(10):1262-1266.
- 14.Sarkar D, Latif SA, Uddin MM, Aich J, Sutradhar SR, Ferdousi S, et al. Studies on serum lipid profile in hypertensive patient. Mymensingh Med J. 2007 Jan;16(1):70-6.
- 15.Hilal Y, Acar TN, Koksal E, Gezmen KM, Akbulut G, Bilici S. The association of anthropometric measurements and lipid profiles in Turkish hypertensive adults. Afr Health Sci. 2011 Sep; 11(3): 407–413.
- 16.Gordon L, Ragoobirsingh D, Morrison EYA, Choo-Kang E, McGrowder D, Martorell E. Lipid Profile of Type 2 Diabetic and Hypertensive Patients in the Jamaican Population. J Lab Physicians. 2010 Jan-Jun; 2(1): 25–30.
- 17.Olsen MH, Wachtell K, Beevers G, Dahlof B, de Simone G, Devereux RB, et al. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2009 Mar;27(3):567-74.
- 18.Dierkes J, Luley C, Westphal S. Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag. 2007 Feb; 3(1): 99–108.

- 19.Zhang YP, Lu MG, Duan DD, Liu YL, Liu M, Li Y, et al. Association between high-density lipoprotein cholesterol and renal function in elderly hypertension: a cross-sectional study in Chinese population. Medicine (Baltimore). 2015 Apr;94(14):e651
- 20.Oda E, Kawai R. High-density lipoprotein cholesterol is positively associated with hypertension in apparently healthy Japanese men and women. Br J Biomed Sci. 2011;68(1):29-33.
- 21.Maggi E, Marchesi E, Ravetta V, Falaschi F, Finardi G, Bellomo G. Low-density lipoprotein oxidation in essential hypertension. J Hypertens. 1993 Oct;11(10):1103-11.
- 22.Selby JV, Peng T, Karter AJ, Alexander M, Sidney S, Lian J, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed

- care population. Am J Manag Care. 2004 Feb;10(2 Pt 2):163-70.
- 23.Onat A, Hergenç G, Sari I, Türkmen S, Can G, Sansoy V. Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study. Am J Hypertens. 2005 Mar;18(3):409-16.
- 24.Eaton CB, Feldman HA, Assaf AR, McPhillips JB, Hume AL, Lasater TM, et al. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. J Fam Pract. 1994 Jan;38(1):17-23.
- 25. Papazafiropoulou A, Skliros E, Sotiropoulos A, Papafragos C, Gikas A, Apostolou O, et al. Prevalence of target organ damage in hypertensive subjects attending primary care: C.V.P.C. study (epidemiological cardio-vascular study in primary care). BMC Fam Pract. 2011 Jul 14;12:75